Skip to main content
pso.arm_.JPG

Risankizumab for Active Psoriatic Arthritis

Nov 26, 2021

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis. I’m excited to report about the combined results from two clinical trials on Risankizumab

Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

Nov 24, 2021

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis). A report from ACR 2021 (Abstract 1713) examined the risk

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 09, 2021
#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
Nov 09, 2021
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
Nov 09, 2021
Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
2 year study shows low rates of radiographic progression in PsA pts on guselkumab #ACR21 @RheumNow Abs#1805https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
Olga Petryna @DrPetryna( View Tweet )
Nov 09, 2021
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
PsA.Hands_.jpg

The Need for Comparative Treatment Trials in Psoriatic Arthritis

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.

Read Article
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 09, 2021
Supporting date for Ixekizumab in PsA with symptoms of axial involvement. 🔹Improvement in QoL (SF-36), ASDAS, BASDAI50 🔹Maintained at 52 weeks 🔹Stricter criteria (younger, ⬆️CRP) showed similar resultshttps://t.co/QSJLQTxLcW#ACR21 Abst#3147 @RheumNow

Pedro Castillo @_Castillo_Pedro( View Tweet )

Nov 08, 2021
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Dr. John Cush @RheumNow( View Tweet )
Nov 08, 2021
Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia ⭐️Anemia resolution associated with improved clinical status #ACR21 #ACRBest Abs#1331 @RheumNow https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 08, 2021
Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment ⭐️no new onset IBD or exacerbation of IBD ⭐️no uveitis, infections, TB Abs#1342 #ACR21 @RheumNow https://t.co/x3OmLgInV0

Robert B Chao, MD @doctorRBC( View Tweet )

Nov 08, 2021
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 08, 2021
Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ
Olga Petryna @DrPetryna( View Tweet )
Nov 08, 2021
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
psA.fil_.Hands_.jpg

Guselkumab in Psoriatic Arthritis

Nov 07, 2021

D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year

Read Article
ACR Best

ACR21 Best Abstracts - Day 1

Nov 07, 2021

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Read Article
×